Oxford Immunotec Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
192
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$441M
Oxford Immunotec General Information
Description
Developer of T Cell-based diagnostic test products and services designed to focus on developing and commercializing proprietary tests for underserved immune-regulated conditions. The company focuses on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions and its research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.
Contact Information
Website
www.oxfordimmunotec.comCorporate Office
- 143 Park Drive
- Milton Park
- Abingdon OX14 4SE
- England, United Kingdom
Corporate Office
- 143 Park Drive
- Milton Park
- Abingdon OX14 4SE
- England, United Kingdom
Oxford Immunotec Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 08-Mar-2021 | $441M | Completed | Generating Revenue | ||
| 13. Secondary Transaction - Open Market | 16-Apr-2018 | Completed | Generating Revenue | |||
| 12. Secondary Transaction - Open Market | 13-Apr-2017 | Completed | Generating Revenue | |||
| 11. Secondary Transaction - Open Market | 21-Mar-2014 | Completed | Generating Revenue | |||
| 10. IPO | 22-Nov-2013 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 04-Jan-2013 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 18-Jun-2012 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 30-Apr-2010 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 29-Oct-2007 | $40M | $57.2M | Completed | Generating Revenue | |
| 5. Secondary Transaction - Private | 01-Mar-2006 | $17.2M | Completed | Startup |
Oxford Immunotec Comparisons
Industry
Financing
Details
Oxford Immunotec Competitors (6)
One of Oxford Immunotec’s 6 competitors is Revvity, a Corporation company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Revvity | Corporation | Waltham, MA | ||||
| Abionic | Venture Capital-Backed | Lausanne, Switzerland | ||||
| Abbott | Corporation | Abbot Park, IL | ||||
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| BioChain Institute | Private Equity-Backed | Newark, CA |
Oxford Immunotec Patents
Oxford Immunotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202105479-D0 | Liquid waste collector and apparatus for performing an automated assay process | Inactive | 16-Apr-2021 | ||
| GB-202105478-D0 | Sieve plate and apparatus for performing an automated elispot process | Inactive | 16-Apr-2021 | ||
| WO-2022219312-A2 | Sieve plate and apparatus for performing an automated elispot process | Inactive | 16-Apr-2021 | ||
| WO-2022219312-A3 | Sieve plate and apparatus for performing an automated elispot process | Inactive | 16-Apr-2021 | ||
| GB-202105476-D0 | Target entity isolation in an assay process | Inactive | 16-Apr-2021 |
Oxford Immunotec Signals
Oxford Immunotec Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AlbionVC | Venture Capital | Minority | ||
| Apollo Global Management | PE/Buyout | Minority | ||
| Dow Venture Capital | Corporate Venture Capital | Minority | ||
| HR Ventures | Corporate Venture Capital | Minority | ||
| Invesco Asset Management | Asset Manager | Minority |
Oxford Immunotec Acquisitions (3)
Oxford Immunotec’s most recent deal was a Merger/Acquisition with Immunetics for . The deal was made on 12-Oct-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Immunetics | 12-Oct-2016 | Merger/Acquisition | Biotechnology | ||
| Imugen | 01-Jul-2016 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Boulder Diagnostics | 31-Jul-2014 | Merger/Acquisition | Biotechnology |
Oxford Immunotec ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Laboratory Equipment and Services
Subindustry
Rank
Percentile
Oxford Immunotec FAQs
-
When was Oxford Immunotec founded?
Oxford Immunotec was founded in 2002.
-
Where is Oxford Immunotec headquartered?
Oxford Immunotec is headquartered in Abingdon, United Kingdom.
-
What is the size of Oxford Immunotec?
Oxford Immunotec has 192 total employees.
-
What industry is Oxford Immunotec in?
Oxford Immunotec’s primary industry is Diagnostic Equipment.
-
Is Oxford Immunotec a private or public company?
Oxford Immunotec is a Private company.
-
What is the current valuation of Oxford Immunotec?
The current valuation of Oxford Immunotec is .
-
What is Oxford Immunotec’s current revenue?
The current revenue for Oxford Immunotec is .
-
How much funding has Oxford Immunotec raised over time?
Oxford Immunotec has raised $187M.
-
Who are Oxford Immunotec’s investors?
AlbionVC, Apollo Global Management, Dow Venture Capital, HR Ventures, and Invesco Asset Management are 5 of 19 investors who have invested in Oxford Immunotec.
-
Who are Oxford Immunotec’s competitors?
Revvity, Abionic, Abbott, Bio-Rad Laboratories, and BioChain Institute are some of the 6 competitors of Oxford Immunotec.
-
When was Oxford Immunotec acquired?
Oxford Immunotec was acquired on 08-Mar-2021.
-
Who acquired Oxford Immunotec?
Oxford Immunotec was acquired by Revvity.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process